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Abstract: InadditiontoantigenpresentationtoCD4+ Tcells, aggregationofcellsurfacemajorhistocompatibility
complex class II (MHC-II) molecules induces signal transduction in antigen presenting cells that
regulate cellular functions. We previously reported that crosslinking of MHC-II induced the endocytosis
of MHC-II, which was associated with decreased surface expression levels in murine dendritic cells
(DCs) and resulted in impaired activation of CD4+ T cells. However, the downstream signal that
induces MHC-II endocytosis remains to be elucidated. In this study, we found that the crosslinking of
MHC-II induced intracellular Ca2+ mobilization, which was necessary for crosslinking-induced MHC-II
endocytosis. We also found that these events were suppressed by inhibitors of Syk and phospholipase
C (PLC). Treatments with a phorbol ester promoted MHC-II endocytosis, whereas inhibitors of protein
kinase C (PKC) suppressed crosslinking-induced endocytosis of MHC-II. These results suggest that
PKC could be involved in this process. Furthermore, crosslinking-induced MHC-II endocytosis was
suppressed by inhibitors of clathrin-dependent endocytosis. Our results indicate that the crosslinking of
MHC-II could stimulate Ca2+ mobilization and induce the clathrin-dependent endocytosis of MHC-II
in murine DCs.
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1. Introduction
Dendritic cells (DCs) are potent antigen presenting cells (APCs) widely distributed in peripheral
tissues. They capture antigens, such as invaded pathogens, and present the antigen-derived peptides
with major histocompatibility antigen class II (MHC-II) molecules on the cell surface. Antigen-specific
CD4+ T cells recognize the antigen peptide-MHC-II complex (pMHC-II) by T cell receptors (TCRs),
which leads to their proliferation and differentiation into effector T cells that initiate an adaptive
immune response to the pathogens [1–5].
In addition to their role in antigen presentation, substantial evidence suggests that an aggregation of
cell surface MHC-II induces signaling inside the cells by regulating the functioning of APCs, including
DCs and B cells [6]. One of the features triggered by MHC-II-induced signaling is the suppression of the
potential of antigen presentation in murine bone marrow-derived DCs (BMDCs). MHC-II crosslinking
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was reported to suppress LPS-induced activation of BMDCs [7]. In addition, we previously reported
that crosslinking of MHC-II induces endocytosis and decreases the expression levels of cell surface
MHC-II, which results in an attenuation of the potential of antigen presentation [8]. However, the signal
transduction and molecular mechanisms that induce endocytosis through MHC-II remain unclear.
Clathrin-dependent endocytosis is one of the pathways through which proteins are transported
from the cell surface to intracellular compartments by clathrin-coated vesicles. During this process,
the GTPase dynamin is required for the endocytic membrane scission process. Many receptors are
internalized through clathrin-dependent and dynamin-dependent endocytosis pathways after ligand
binding [9]. On the other hand, some cell surface proteins are internalized by clathrin-independent
endocytosis pathways [10,11]. In steady-state DCs, it has been reported that pMHC-II is internalized
by clathrin-independent and dynamin-independent pathways [12]. However, it is unclear whether
crosslinking-induced endocytosis of MHC-II is attributed to increased steady-state clathrin-independent
endocytosis or the induction of an alternative endocytosis route.
In this study, we aimed to investigate the signal transduction pathways involved in crosslinking-
induced MHC-II endocytosis in BMDCs.
2. Materials and Methods
2.1. Materials
The following materials were obtained from the sources indicated: anti-mouse MHC-II antibody
(clone 11-5.2) from Biolegend (San Diego, CA, USA); 12-O-tetradecanoyl phorbol 13-acetate (TPA),
cytochalasin D, dynasore, chlorpromazine, staurosporine, and piceatannol from Sigma-Aldrich (St. Louis,
MO, USA), Fura-2/AM from Dojindo (Kumamoto, Japan), 1,2-bis(o-aminophenoxy)ethane- N,N,N′,N′-
tetraacetic acid tetra(acetoxymethyl) ester (BAPTA-AM), U-73122, PD98059, SB203580, and SP600125
from Merck Millipore (Darmstadt, Germany), GF 109203X and R406 from Cayman Chemical (Ann Arbor,
MI, USA), recombinant murine granulocyte macrophage colony-stimulating factor (GM-CSF) from
Peprotech (Rocky Hill, NJ, USA), anti-FcγRII/RIII (clone 2.4G2) antibody and anti-clathrin heavy chain
(CHC) antibody from BD Biosciences (San Jose, CA, USA), Alexa Fluor 488-labeled goat anti-mouse IgG1
antibody and Alexa Fluor 546-labeled goat anti-mouse IgG2b antibody from Thermo Fisher Scientific
(Waltham, MA, USA). All other chemicals were commercial products of a reagent grade.
2.2. Mice
Specific-pathogen-free, male B10.BR mice (H-2k) were obtained from Japan SLC (Hamamatsu,
Japan), and all mice were kept in a specific-pathogen-free animal facility at Okayama University.
The Committee on Animal Experiments of Okayama University (approval numbers OKU-2015042
(date of approval: 1 April 2015) and OKU-2018087 (date of approval: 1 April 2018)) approved this study.
2.3. Preparation of BMDCs
BMDCs were prepared following the standard protocol [13]. Briefly, bone marrow cells obtained
from B10.BR mice were cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS),
2-mercaptoethanol (50 µM), penicillin (100 units/mL), and streptomycin (100 µg/mL) in the presence of
10 ng/mL GM-CSF for 7 days. More than 90% of the obtained cells were CD11c+ and MHC-II+ at day 7.
2.4. Crosslinking of Cell Surface MHC-II
BMDCs were incubated with an anti-MHC-II antibody (clone 11-5.2, 5 µg/mL) in the presence
of an anti-FcγRII/RIII antibody (clone 2.4G2) in FACS staining medium (phosphate-buffered saline
(PBS) (−) containing 2% FBS) for 30 min on ice. The cells were washed and surface MHC-II molecules
were crosslinked with a biotinylated goat anti-mouse IgG antibody (5 µg/mL) in RPMI-1640 medium
containing 10% FBS, 2-mercaptoethanol (50µM), penicillin (100 units/mL), and streptomycin (100µg/mL)
for 30 min at 37 ◦C. After washing with FACS staining medium, the cells were incubated with PE-labeled
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streptavidin for 30 min on ice for detection of the remaining cell surface MHC-II. The fluorescence
intensity was measured using a flow cytometer (FACS Calibur, Becton Dickinson, Franklin Lakes,
NJ, and Gallios, Beckman Coulter, Brea, CA, USA). The results were presented as a percentage of the
fluorescence intensity of the cells placed on ice.
2.5. Measurement of Cytosolic Ca2+ Concentrations
Cells were loaded with 6 µM Fura-2/AM in modified Tyrode’s buffer (10 mM HEPES-NaOH, pH
7.3, 130 mM NaCl, 5 mM KCl, 1.4 mM CaCl2, 1 mM MgCl2, 5.6 mM glucose, and 0.1% bovine serum
albumin (BSA)) containing 2.5 mM probenecid for 45 min at room temperature. Fluorescence intensities
were measured with a fluorescence spectrometer (CAF-110, Jasco, Tokyo, Japan) with an excitation
wavelength of 340 or 380 nm and an emission wavelength of 510 nm. Cytosolic Ca2+ concentration
was expressed as the 340 nm/380 nm ratio.
2.6. Immunofluorescence Microscopy
Immunofluorescence microscopy analyses were performed as described previously [14]. BMDCs
were seeded on poly-l-lysine coated glass cover slips and allowed to adhere for 30 min at room
temperature. The cells were incubated with an anti-MHC-II antibody (clone 11-5.2, 5 µg/mL) for 30 min
at 4 ◦C. The cells were washed and then crosslinked with an Alexa Fluor 546-labeled anti-mouse IgG2b
antibody (5 µg/mL) for the periods indicated at 37 ◦C. The cells were fixed with 4% paraformaldehyde
in PBS for 20 min at 4 ◦C and permeabilized with 0.1% saponin in PBS at room temperature. After the
cells were blocked with 2% normal goat serum for 1 h at room temperature, the cells were stained
with an anti-CHC antibody for 1 h at 4 ◦C. The cells were washed and stained with an Alexa Fluor
488-labeled anti-mouse IgG1 antibody as the secondary antibody. The cells were visualized using
confocal laser scanning microscopy (OLYMPUS FV300 and FV1200, Tokyo, Japan). For quantitative
fluorescence analysis, Manders’ overlay coefficients were calculated using ImageJ software with the
Coloc2 plugin, using at least 10 cells in each analysis [15].
2.7. Statistical Analysis
Data are presented as the mean ± SEM. Statistical significance for comparisons between the two
groups was determined using the Student’s t-test. Statistical significance for comparisons among
multiple groups was determined using one-way ANOVA. Additional comparisons were made using
Dunnett’s Multiple Comparison test to compare with the control groups, or the Tukey-Kramer Multiple
Comparison test for all pairs of column comparisons.
3. Results
3.1. Crosslinking-Induced Intracellular Ca2+ Mobilization is Required for Endocytosis of MHC-II
As previously reported [8], MHC-II was spontaneously internalized, and crosslinking of MHC-II
enhanced a down-regulation of cell surface MHC-II expression in BMDCs (Figure 1A). In this case,
we investigated the signaling mechanisms involved in the endocytosis of MHC-II. Since MHC-II
crosslinking was reported to induce intracellular Ca2+ mobilization in B cells [16–18], we measured
the cytosolic Ca2+ levels after MHC-II crosslinking in BMDCs and found that MHC-II crosslinking
induced Ca2+ mobilization (Figure 1B). We then examined the effects of cytosolic Ca2+ depletion in
spontaneous and crosslinking-induced endocytosis of MHC-II using a Ca2+ chelator, BAPTA-AM.
While BAPTA-AM treatment did not affect the spontaneous (crosslink (−)) endocytosis of MHC-II, it
inhibited the crosslinking-induced endocytosis of MHC-II (Figure 1C). We confirmed that BAPTA-AM
treatment did not affect the distribution of MHC-II expression in BMDCs (Figure S1). These results
indicate that intracellular Ca2+ mobilization is required for crosslinking-induced endocytosis of MHC-II.
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pretreated with vehicle (0.1% dimethyl sulfoxide (DMSO)) or BAPTA-AM (50 µM) for 30 min at 37 
°C. The cell surface MHC-II was crosslinked with an anti-MHC-II antibody for 30 min. The remaining 
cell surface MHC-II was detected by flow cytometry. Values of ** p < 0.01 are regarded as significant. 
3.2. Intracellular Ca2+ Mobilization Induces Endocytosis of MHC-II 
Next, we investigated whether intracellular Ca2+ mobilization accelerates the endocytosis of 
MHC-II by examining the effects of a reagent that induces intracellular Ca2+ mobilization. An 
endoplasmic reticulum calcium ATPase inhibitor, thapsigargin, is known to induce Ca2+ mobilization 
in many cell types and we confirmed that thapsigargin induced intracellular Ca2+ mobilization in 
BMDCs (Figure 2A). We then investigated the effects of thapsigargin on MHC-II endocytosis and 
found that thapsigargin treatment induced significant levels of endocytosis of MHC-II (Figure 2B). 
These results suggest that intracellular Ca2+ mobilization can induce MHC-II endocytosis. 
 
Figure 2. Intracellular Ca2+ mobilization induces endocytosis of MHC-II. (A) BMDCs were stimulated 
with or without thapsigargin and cytosolic Ca2+ mobilization was detected using Fura-2/AM. Bars = 1 
min. Relative changes in the cytosolic Ca2+ concentrations are expressed as the ratio of fluorescence 
intensity at 340/380 nm. (B) BMDCs were incubated with an anti-MHC-II antibody for 30 min at 4 °C. 
The cells were washed and stimulated with thapsigargin for 30 min at 37 °C. The remaining cell 
surface anti-MHC-II antibody was detected using a PE-labeled anti-mouse IgG antibody. Values of *p 
< 0.05, **p < 0.01 are regarded as significant. 
3.3. Crosslinking-Induced Endocytosis of MHC-II is Syk and Phospholipase C (PLC)-Dependent 
Figure 1. Intracellular Ca2+ mobilization is required for crosslinking-induced endocytosis of major
histocompatibility complex class II (MHC-II). (A) Bone marrow-derived dendritic cells (BMDCs) were
incubated with an anti-MHC-II antibody for 30 min at 4 ◦C. For crosslinking, the cell surface MHC-II was
incubated with a biotin-labeled anti-mouse IgG antibody for 30 min at 37 ◦C. The remaining cell surface
MHC-II was detected using PE-labeled streptavidin. (B) BMDCs were crosslinked with an anti-MHC-II
antibody and an anti-mouse IgG antibody. The cytosolic Ca2+ mobilization after stimulation was detected
using Fura-2/AM. Bars = 1 min. Relative changes in the cytosolic Ca2+ concentrations are expressed as
the ratio of fluorescence intensity at 340/380 nm. (C) BMDCs were pretreated with vehicle (0.1% dimethyl
sulfoxide (DMSO)) or BAPTA-AM (50 µM) for 30 min at 37 ◦C. The cell surface MHC-II was crosslinked
with an anti-MHC-II antibody for 30 min. The remaining cell surface MHC-II was detected by flow
cytometry. Values of ** p < 0.01 are regarded as significant.
3.2. Intracellular Ca2+ Mobilization Induces Endocytosis of MHC-II
Next, we investigated whether intracellular Ca2+ mobilization accelerates the endocytosis of MHC-II
by examining the effects of a reagent that induces intracellular Ca2+ mobilization. An endoplasmic
reticulum calcium ATPase inhibitor, thapsigargin, is known to induce Ca2+ mobilization in many
cell types and we confirmed that thapsigargin induced intracellular Ca2+ mobilization in BMDCs
(Figure 2A). We then investigated the effects of thapsigargin on MHC-II endocytosis and found that
thapsigargin treatment induced significant levels of endocytosis of MHC-II (Figure 2B). These results
suggest that intracellular Ca2+ mobilization can induce MHC-II endocytosis.
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Figure 2. Intracel ular Ca2+ c tosis f -I . ( ) B DCs ere stimulated
with or without thapsigargin and cytosolic Ca2+ obilization was detected using Fura-2/AM. Bars = 1
min. Relative changes in the cytosolic Ca2+ c tr ti r ex resse as the ratio of fluorescence
intensity at 340/380 nm. (B) B DCs were incubated with an anti- HC-II antibody for 30 min at 4 ◦ .
The cells were washed and stimulated with thapsigargin for 30 min at 37 ◦C. The remaining cell surface
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3.3. Crosslinking-Induced Endocytosis of MHC-II is Syk and Phospholipase C (PLC)-Dependent
Activation of an immunoreceptor tyrosine-based activation motif (ITAM) containing C-type lectin
receptor, Dectin-1, was found to induce intracellular Ca2+ mobilization, which was mediated by Syk
tyrosine kinase-mediated PLCγ activation, in BMDCs [19]. It was also reported that MHC-II interacted
with the ITAM-containing adaptor protein, FcγRγ, in BMDCs, and that MHC-II crosslinking induces
tyrosine phosphorylation of cellular proteins [7]. Therefore, we examined the contribution of Syk and
phospholipase C (PLC) using inhibitors against these molecules. Crosslinking-induced endocytosis of
MHC-II was suppressed by Syk inhibitors, (piceatannol and R406), and a PLC inhibitor (U73122) (Figure 3).
We then examined the effect of piceatannol and U73122 on intracellular Ca2+ mobilization, and found
that both inhibitors suppressed Ca2+ mobilization induced by MHC-II crosslinking (Figure 4A,B). These
results suggest that Syk and PLC are potentially involved in intracellular Ca2+ mobilization and MHC-II
endocytosis induced by crosslinking of MHC-II.
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BMDCs were pre-incubated with (A) piceatannol (50 µM) or (B) U73122 (10 µM) for 30 min at 37 ◦C.
The cytosolic Ca2+ mobilization after MHC-II crosslinking was measured using Fura-2/AM. Relative changes
in the cytosolic Ca2+ concentrations are expressed as the ratio of fluorescence intensity at 340/380 nm.
Bars = 1 min. Values of * p < 0.05, ** p < 0.01 are regarded as significant.
3.4. Protein Kinase C (PKC) Activation is Involved in MHC-II Endocytosis
One of the signaling molecules activated by intracellular Ca2+ mobilization is PKC. We, therefore,
examined the effects of Ca2+ ionophore, A23,187, and a phorbol ester, TPA, which are known activators of
conventional PKC isoforms, on MHC-II endocytosis. Both TPA and A23187 induced MHC-II endocytosis
(Figure 5A). Furthermore, pretreatment with broad-spectrum PKC inhibitors, staurosporine, or GF109203X
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suppressed crosslinking-induced MHC-II endocytosis (Figure 5B,C). These results suggest that Ca2+-
dependent PKC activation is involved in MHC-II endocytosis.
Activation of mitogen-activated protein (MAP) kinases is required for the endocytosis of several cell
surface receptors such as epidermal growth factor receptor (EGFR) [20]. Furthermore, MHC-II-induced
signaling has been reported to activate ERK, which is one of the MAP kinases, in BMDCs [7]. Therefore,
we investigated the effect of MAP kinase inhibitors on MHC-II endocytosis. Pretreatment with PD98059
(a MEK inhibitor), SB203580 (a p38 MAPK inhibitor), or SP600125 (a JNK inhibitor) did not affect
crosslinking-induced MHC-II endocytosis (Figure 5D–F), which suggests that MAP kinases are not
involved in this process.
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majority of the MHC-II signal was found inside the cells 10 min after crosslinking and did not overlap 
with those of CHC (Figure 7A). In agreement with a previous study [21,22], chlorpromazine 
treatment prevented redistribution of CHC (Figure 7B). In the cells treated with chlorpromazine, 
most of the MHC-II remained at the cell surface for 2, 5, and 10 min after crosslinking and co-
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tetradecanoyl phorbol 13-acetate (TPA) (100 nM) a d A23187 (1µM) for 30 min at 37 ◦C. The remaining cell
surface anti-MHC-II ntibody was detected using a PE-labeled anti-mouse IgG ntibody. (B,C) BMDCs
were pre-incubated with stauros orine for 15 min or GF109203X for 30 min at the indicated concentrations
of 37 ◦C. The cell surface MHC-II was crosslinked using an anti-MHC-II antibody. (D–F) BMDCs were
pre-incubated with SB203580 (10 µM) for 30 min, PD98059 (50 µM) for 15 min, or SP600125 (20 µM) for
15 min, at 37 ◦C. The cell surface MHC-II was crosslinked using an anti-MHC-II antibody for 30 min.
The remaining cell surface MHC-II was detected by flow cytometry. Values of * p < 0.05, ** p < 0.01 are
regarded as significant.
3.5. Crosslinking-Induced Endocytosis of MHC-II is a Clathrin-Dependent Response
Next, we investigated the endocytosis pathway of MHC-II upon its crosslinking. Cytochalasin
D, which inhibits several endocytosis pathways by inhibiting actin polymerization, suppressed
crosslinking-induced MHC-II endocytosis (Figure 6). In addition, a dynamin inhibitor, dynasore, and a
clathrin-mediated endocytosis inhibitor, chlorpromazine, suppressed crosslinking-induced MHC-II
endocytosis (Figure 6). This result suggests that crosslinking-induced MHC-II endocytosis is dependent
on both dynamin and clathrin.
Clathrin-dependent endocytosis requires a transient interaction between clathrin and the target
protein. The degree of co-localization between internalized MHC-II and the clathrin heavy chain (CHC)
was quantified by calculating Manders’ overlap coefficient. Increases in co-localization of MHC-II
with CHC just beneath the cell surface were observed 2 and 5 min after crosslinking. The majority
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of the MHC-II signal was found inside the cells 10 min after crosslinking and did not overlap with
those of CHC (Figure 7A). In agreement with a previous study [21,22], chlorpromazine treatment
prevented redistribution of CHC (Figure 7B). In the cells treated with chlorpromazine, most of the
MHC-II remained at the cell surface for 2, 5, and 10 min after crosslinking and co-localization of MHC-II
with CHC was hardly observed. These results indicate that crosslinking-induced MHC-II endocytosis
is clathrin-dependent. We then investigated the effects of inhibitors against crosslinking-induced
signaling on co-localization of MHC-II and clathrin after crosslinking. Similar to the result presented
in Figure 7, an increase in co-localization of MHC-II and clathrin was observed after crosslinking for
2 min in control-pretreated cells (Figure 8A). When the BMDCs were pretreated with BAPTA-AM,
R406, and U73122, the co-localizations of MHC-II and clathrin was not enhanced (Figure 8B–D). These
results suggested that MHC-II crosslinking-induced signaling induces the co-localization of MHC-II
and clathrin.
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37 ◦C. The cell surface MHC-II was crosslinked with an anti-MHC-II antibody for 30 min. The remaining
cell surface MHC-II was detected by flow cytometry. Values of * p < 0.05 are regarded as significant.
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Figure 7. Crosslinking-induced endocytosis of MHC-II is clathrin-dependent. (A) BMDCs were incubated
with an anti-MHC-II antibody for 30 min at 4 ◦C. (B) BMDCs pre-incubated with chlorpromazine (30 µM)
for 30 min at 37 ◦C were incubated with an anti-MHC-II antibody for 30 min at 4 ◦C. The cells were
washed and crosslinked with an Alexa 546-labeled anti-mouse IgG for the indicated time periods at 37 ◦C.
The cells were fixed, permeabilized, and stained with an anti-clathrin heavy chain (CHC) antibody and
an Alexa Fluor 488-labeled secondary antibody. bars = 2µm. Co-localization of MHC-II and CHC was
quantified by calculating Manders’ coefficients M1 (green pixels (CHC) overlapping red pixels (MHC-II))
and M2 (red pixels overlapping green pixels) using ImageJ software. Values are presented as the mean ±
SEM (n = 10), * p < 0.05, ** p < 0.01.
Cells 2020, 9, 1810 8 of 12
Cells 2020, 9, x FOR PEER REVIEW 8 of 12 
Figure 8. Effect of inhibitors on crosslinking-induced co-localization of MHC-II and clathrin. BMDCs 
pre-incubated with (A) control (0.1% DMSO), (B) BAPTA-AM (50 µM), (C) R406 (3 µM), or (D) U73122 
(10 µM) for 30 min at 37 °C. The cell surface MHC-II was crosslinked with anti-MHC-II antibody. The 
co-localization of MHC-II and CHC was analyzed as described in Figure 7. Values are presented as 
the mean ± SEM (n = 10), * p < 0.05, ** p < 0.01. 
4. Discussion
In this study, we investigated the MHC-II crosslinking-induced signaling pathway and 
molecular mechanisms involved in the endocytosis of MHC-II in murine BMDCs (Figure 9). There 
are various reports on the function of MHC-II-induced signals [6]. Liang et al. demonstrated that 
MHC-II crosslinking suppresses Toll-like receptor (TLR) signaling-induced upregulation of CD86 
and CD40 in murine BMDCs [7]. They investigated the mechanism responsible for the suppression 
and found that MHC-II crosslinking induces activation of ERK via the ITAM-containing adapter 
protein, FcγRγ, which activates a tyrosine phosphatase SHP-1. They also showed that an inhibitor of 
Syk did not affect the MHC-II crosslinking-induced suppression of TLR signaling. In our study, we 
investigated the MHC-II crosslinking-induced signaling that induces MHC-II endocytosis, and found 
that Syk-and PLC-mediated Ca2+ mobilization is involved in MHC-II endocytosis. Crosslinking-
induced MHC-II endocytosis was not affected by ERK inhibition. These results suggest that MHC-II 
crosslinking activates multiple signaling pathways and that these signals act in different ways, which 
might impair the ability of antigen-presentation in BMDCs. Since FcγRγ is known to be involved in 
the activation of Syk in several cells [23], a similar signaling pathway may be utilized in BMDCs upon 
MHC-II crosslinking. Alternatively, since MHC-II is reported to interact with other membrane 
proteins in B cells, such as CD79a and CD79b [17], SCIMP [24], and MPYS/STING [25]. MHC-II might 
interact with adapter proteins other than FcγRγ to induce Syk/PLC signaling in BMDCs. Further 
analysis is required to clarify the signal transduction form MHC-II crosslinking to cytosolic Ca2+ 
mobilization. 
. ff i l t ri .
i ate it ( ) t l . ), ( ) - (50 ), ( ) ),
f r 30 min at 37 ◦C. The cell surface MHC-II was crosslinked with anti-MHC-II antibody.
The co- ocalization of MHC-II and CHC w s nalyzed as described in Figure 7. Values are r
10), * p < 0.05, * p < 0.01.
4. Discussion
In this study, we investigated the MHC-II crosslinking-induced signaling pathway and molecular
mechanisms involved in the endocytosis of MHC-II in murine BMDCs (Figure 9). There are various
reports on the function of MHC-II-induced signals [6]. Liang et al. demonstrated that MHC-II crosslinking
suppresses Toll-like receptor (TLR) signaling-induced upregulation of CD86 and CD40 in murine BMDCs [7].
They investigated the mechanism responsible for the suppression and found that MHC-II crosslinking
induces activation of ERK via the ITAM-containing adapter protein, FcγRγ, which activates a tyrosine
phosphatase SHP-1. They also showed that an inhibitor of Syk did not affect the MHC-II crosslinking-
induced suppression of TLR signaling. In our study, we investigated the MHC-II crosslinking-induced
signaling that induces MHC-II endocytosis, and found that Syk-and PLC-mediated Ca2+ mobilization
is involved in MHC-II endocytosis. Crosslinking-induced MHC-II endocytosis was not affected by
ERK inhibition. These results suggest that MHC-II crosslinking activates multiple signaling pathways
and that these signals act in different ways, which might impair the ability of antigen-presentation in
BMDCs. Since FcγRγ is known to be involved in the activation of Syk in several cells [23], a similar
signaling pathway may be utilized in BMDCs upon MHC-II crosslinking. Alternatively, since MHC-II
is reported to interact with other membrane proteins in B cells, such as CD79a and CD79b [17],
SCIMP [24], and MPYS/STING [25]. MHC-II might interact with adapter proteins other than FcγRγ to
induce Syk/PLC signaling in BMDCs. Further analysis is required to clarify the signal transduction
form MHC-II crosslinking to cytosolic Ca2+ mobilization.
In this study, we found that MHC-II crosslinking induced Ca2+ mobilization and that inhibition
of Ca2+ mobilization by inhibitors suppressed MHC-II endocytosis. These results suggested that Ca2+
mobilization is required for crosslinking-induced MHC-II endocytosis. Although thapsigargin promoted
Ca2+ mobilization and MHC-II endocytosis, the effect on MHC-II endocytosis was weaker than that on
MHC-II crosslinking. Since crosslinking is known to promote the phosphorylation of various proteins
in BMDCs [7], MHC-II crosslinking may induce signaling pathways other than Ca2+ mobilization that
result in enhanced MHC-II endocytosis.
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Figure 9. Schematic overview of MHC-II crosslinking induced signaling, which induces MHC-II
endocytosis in BMDCs. MHC-II crosslinking induces Syk and PLC-mediated cytosolic Ca2+ mobilization.
Activation of PKC, which is one of the molecules activated by cytosolic Ca2+ mobilization, induces
endocytosis of MHC-II. These signal transductions induce colocalization of MHC-II with clathrin,
which results in an induction of clathrin-dependent and dynamin-dependent MHC-II endocytosis.
Crosslinking-induced MHC-II endocytosis was inhibited by PKC inhibitors. In addition, endocytosis
of MHC-II was promoted by some PKC activators without MHC-II crosslinking. These results suggest
that PKC may play an important role in the process. Crosslinking of MHC-II was reported to induce
activation of PKCβ in human B cells [26,27], and of PKCδ in human monocyte-derived dendritic
cells [28,29]. These PKC isoforms may also be activated in BMDCs by MHC-II crosslinking and regulate
the induction of MHC-II endocytosis. Several PKC isoforms are reported to be involved in ligand-induced
endocytosis of some membrane proteins. Activation of PKCβII is required for ligand-induced endocytosis
of dopamine receptor D3 [30], and activation of PKCα is necessary for the down-regulation of TCRs in
antigen-activated T cells. These PKC isoforms may be activated by MHC-II crosslinking and may be
involved in endocytosis of MHC-II in BMDCs. Further analysis is required to determine which PKC
isoforms could be activated upon crosslinking.
Induction of clathrin-dependent endocytosis is regulated by PKC for several proteins. Endocytosis of
TCRs induced by ligand binding is clathrin-dependent [31,32]. In this case, PKC-mediated phosphorylation
of Ser 163 ofβ-arrestin-1 regulates the TCR endocytosis [33,34]. Activation of PKC was reported to induce
clathrin-dependent endocytosis of the glutamate transporter, GLT-1, and the human organic cation
transporter (hOAT). In this case, a ubiquitin E3 ligase, Nedd 4-2, is activated by PKCs. The activated
Nedd 4-2 ubiquitinates GLT-1 and hOAT, which results in their endocytosis [35,36]. Although MHC-II
is known to be ubiquitinated at Lys 225, a K225R point-mutation did not affect crosslinking-induced
MHC-II endocytosis [8], which suggests that direct ubiquitination of MHC-II is not involved in
crosslinking-induced MHC-II endocytosis.
We examined the molecular mechanisms of crosslinking-induced MHC-II endocytosis using
several endocytosis inhibitors. Crosslinking-induced endocytosis was suppressed by chlorpromazine
and dynasore, which indicates that crosslinking-induced MHC-II endocytosis is clathrin and dynamin-
dependent. The signaling inhibitors, BAPTA-AM, R406, and U73122, also suppressed co-localization
of MHC-II and clathrin. Crosslinking-induced signals likely promote the transition of an MHC-II to
the clathrin-dependent endocytosis pathway.
In steady-state DCs, MHC-II is reported to internalize via clathrin-independent and dynamin-
independent pathways [12]. We found that BAPTA-AM treatment did not affect the steady-state endocytosis
of MHC-II. These results suggest that crosslinking does not simply accelerate the existing endocytosis pathway
but induces an alternative endocytosis pathway. We previously found that crosslinking-induced MHC-II
endocytosis was inhibited by methyl-β-cyclodextrin (MCD) treatment, which raises the possibility that lipid
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rafts could be involved in the process [8]. Although it is well known that MCD blocks clathrin-independent
endocytosis, disruption of lipid rafts is also reported to inhibit the clathrin-dependent endocytosis of some
proteins. For example, endocytosis of B cell receptors (BCRs) after crosslinking is suppressed by disruption
of lipid rafts, even though endocytosis of BCRs is clathrin-dependent in B cells [37,38]. MCD treatment may
disrupt the association of signaling molecules in the lipid raft, which results in inhibition of intracellular
signal transduction triggered by MHC-II ligation.
In summary, we investigated the molecular mechanisms that could potentially regulate crosslinking-
induced MHC-II endocytosis. Our results suggested that MHC-II crosslinking-induced intracellular
Ca2+ mobilization is required to induce MHC-II endocytosis, and that crosslinking-induced MHC-II
endocytosis is clathrin and dynamin-dependent. Since MHC-II endocytosis was suppressed by PKC
inhibitors and promoted by PKC activators, intracellular Ca2+ mobilization by MHC-II crosslinking
may induce activation of PKCs. This activation results in induction of MHC-II endocytosis. The present
study suggested that intracellular Ca2+ mobilization could be one of the factors determining the cell
surface expression levels of MHC-II in DCs.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/8/1810/s1.
Figure S1: Effect of crosslinking and BAPTA-AM on endocytosis of MHC-II.
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